Pankaine Spinal Heavy (Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine works by blocking voltage‑gated sodium channels on nerve fibers. This inhibition prevents the initiation and propagation of action potentials, leading to a reversible loss of sensation and motor function in the area supplied by the affected spinal nerves.

The dose of Pankaine Spinal Heavy is determined by the prescribing clinician based on the specific procedure, patient characteristics, and desired level of block. The prescriber selects the appropriate volume and concentration to achieve safe and effective anesthesia.

Bupivacaine may be used during labor when the benefits outweigh potential risks, but it is classified as a category C drug for pregnancy. It is not recommended for routine use in breastfeeding mothers unless the prescriber determines that the advantages justify any possible risk to the infant.

To request Pankaine Spinal Heavy, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Bupivacaine provides a longer duration of action compared with agents such as lidocaine or mepivacaine, making it suitable for prolonged surgical or obstetric procedures. However, its higher potency also carries a greater risk of systemic toxicity, so careful dosing and monitoring are essential.

Pankaine Spinal Heavy should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture and extreme temperature fluctuations to maintain sterility and potency.

The product is administered by a trained healthcare professional via a spinal (intrathecal) injection. After aseptic preparation, a fine‑gauge needle is introduced into the subarachnoid space, and the calculated volume of bupivacaine solution is injected to achieve the desired block.

Serious risks include local anesthetic systemic toxicity (LAST) manifesting as seizures or cardiac arrhythmias, high spinal block leading to respiratory compromise, and rare allergic reactions. Prompt recognition and treatment of these events are critical for patient safety.

Patients with known hypersensitivity to amide‑type local anesthetics, those with severe cardiac conduction disorders, uncontrolled hypotension, or a history of spinal hematoma should avoid using Pankaine Spinal Heavy. Contraindications are determined by the prescribing clinician.